晚期发作的crizotinib相关的脏囊与随后的回归后剂量减少:一个病例报告.
Joon-Young Yoon1,2, Won Gi Jeong2,3, Yoo-Duk Choi2,4
1Department of Internal Medicine, Division of Pulmonology, Chonnam National University Medical School, Hwasun, Jeonnam, South Korea.
Thoracic cancer
|June 21, 2025
概括
对ALK阳性肺癌的克里佐替尼治疗可能会导致罕见的囊. 减少剂量有助于控制这些囊,允许继续治疗和控制瘤.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 克里佐替尼是一种ALK/ROS1/c-MET抑制剂,有效治疗ALK阳性非小细胞肺癌 (NSCLC).
- 与克里佐替尼相关的囊 (CARCs) 是这种向治疗的罕见但显著的不良影响.
- 长期使用向疗法需要对晚期出现的毒性保持警.
研究的目的:
- 报告ALK阳性NSCLC患者晚期发病crizotinib相关囊 (CARCs) 的病例.
- 为了说明CARCs的诊断挑战和管理策略.
- 强调在长期癌症治疗中识别和管理晚发性毒性的重要性.
主要方法:
- 一名68岁的韩国男性患有ALK阳性NSCLC,他接受了crizotinib治疗4年.
- 患者患有复杂的囊,最初怀疑是或瘤,需要手术切除.
- 复发性囊引发了对CARCs的怀疑,导致减少crizotinib的剂量.
主要成果:
- 对于最初的复杂囊,进行了手术切除.
- 在持续的crizotinib治疗期间出现了复发性囊.
- 减少crizotinib剂量导致囊回归,同时保持有效的瘤控制.
结论:
- 晚期发作的crizotinib相关囊 (CARCs) 即使经过多年的治疗后也可能发生.
- 多学科评估对于诊断和管理CARC至关重要.
- 量身定制的crizotinib剂量调整可以有效地管理CARC,而不会影响瘤结果.
相关概念视频
01:11Renal Failure: Dose Adjustments
167
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
167
01:29Acute Kidney Injury III: Clinical Manifestations
105
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
105
01:30Urinary Tract Calculi III: Medical Management
29
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
29
01:25Renal Drug Excretion: Tubular Reabsorption
360
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
360
01:28Urinary Tract Calculi I: Introduction
55
Renal calculi, or kidney stones, are solid deposits of minerals and salts formed inside the kidneys. In medical terminology, "calculus" refers to the stone itself, while "lithiasis" describes the process of stone formation. Depending on their location within the urinary system, these stones may be classified as either urolithiasis, when situated within the urinary tract, or nephrolithiasis, when located within the kidneys. Each term signifies the specific impact of the stone.Predisposition...
55
01:28Renal Drug Excretion: Tubular Secretion
373
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
373